SPIN·DETECTOR

How the coverage framed it

Coverage of the FDA's approval of the Roche and Eli Lilly Alzheimer's blood test was essentially uniform across outlets, with a bias spread of exactly 0.0 points. Both Forbes and the Wall Street Journal used neutral, factual language with no ideological coloring. The only meaningful difference between the two headlines is a minor word choice: Forbes used "clears" ("FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test") while the Wall Street Journal used "approves" ("FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly"). Both verbs are standard regulatory terminology carrying no discernible political valence. Similarly, both outlets straightforwardly attributed the test to the two pharmaceutical companies and identified the FDA as the approving body. The shared framing reflects a wire-service style that treats the story as a straightforward regulatory development, with no apparent attempt by either outlet to spin the news toward a particular ideological audience.